Guggenheim Downgrades Tenax Therapeutics to Neutral After LEVEL Data at ESC 2026
Tenax’s TNX-103 missed the LEVEL primary endpoint. Guggenheim cites encouraging subgroup data in sicker patients but says more work and longer studies may be needed.
/ 491 items
#XY Event-Driven Stocks↓
Lilly Acquires Merida to Advance Treatments for Autoimmune and Allergic Diseases
Eli Lilly will acquire Merida Biosciences for up to $2.875 billion. Merida aims to remove disease-causing antibodies in Graves’ disease, TED and allergies.
BioMarin Stock Jumps After Settling Yuviwel Patent Fight With Ascendis
BioMarin and Ascendis end all Yuviwel patent fights. Ascendis will pay 20% on U.S. sales and 18% in the EU, Brazil, and South Korea until 2030.
Modest Gains and Extra Safety Flags Sink Cytokinetics After ESC Data
Detailed ACACIA results delivered statistical success without a bigger commercial or safety story.
BioNTech Stops Phase 2 Trial of Personalized mRNA Vaccine in High-Risk Colorectal Cancer
BioNTech terminated BNT122-01 after the DSMB found an OS imbalance and said continuing was unlikely to change the outcome.
After Hunter Syndrome Setback, New Regenxbio Director Invests Nearly $1 Million
Newly appointed Regenxbio director Greg Ciongoli bought 102,603 shares for about $950,000 days after an FDA hold on Hunter syndrome therapy RGX-121.